Pampa Energía S.A.
PAM News Today: Stay Updated with the Latest Pampa Energía S.A. News in Real Time
Find PAM news now at Meyka AI. Stay informed with the latest Pampa Energía S.A. stocks updates, including price news, market analysis, and expert insights.
ADXN.SW Stock Surges 8.7% as Addex Therapeutics Nears Earnings
ADXN.SW stock jumps 8.7% to CHF0.0498 on SIX ahead of April 27 earnings. Biotech firm faces profitability challenges but shows momentum.
ADXN.SW Stock Rises 5.5% Ahead of April 27 Earnings Report
ADXN.SW stock climbs 5.5% to CHF 0.0458 on SIX ahead of Addex Therapeutics earnings announcement on April 27, 2026.
Chavez-DeRemer Resigns April 22: Trump Cabinet Crisis Deepens
Labor Secretary Lori Chavez-DeRemer resigns April 22 after abuse of power allegations. Third Trump Cabinet member to depart.
GALP.LS Stock Rises 1.19% Ahead of April 27 Earnings Report
GALP.LS stock gained 1.19% to €19.13 on EURONEXT. Galp Energia reports Q1 earnings April 27 with analyst expectations of €0.21 EPS.
PAM Director Mindlin Sells 1.68M Shares on April 16, 2026
Pampa Energía director Mindlin Marcos Marcelo sold 1.68M shares at $3.54 per share on April 16, 2026. SEC filing reveals $5.9M transaction.
ADXN.SW Stock Surges 8.5% on April 16, 2026 – Addex Therapeutics Gains
ADXN.SW stock jumps 8.5% to CHF 0.051 on SIX. Addex Therapeutics gains amid biotech volatility and CNS drug pipeline developments.
April 9: DOJ Says Pam Bondi Won’t Testify; House Eyes Contempt in Epstein Probe
Pam Bondi deposition fight heats up: DOJ says she won’t testify April 14, House Oversight weighs contempt. What this means for investors and regulatory risk.
April 4: DOJ Power Shift Puts Antitrust, M&A Approvals in Flux
Pam Bondi’s removal and Todd Blanche’s rise at the DOJ introduce fresh uncertainty for antitrust enforcement and M&A approvals. Here is what Hong Kong investors should watch now.
Todd Blanche Today: DOJ Shake-Up Raises M&A, Antitrust Risk — April 03
Todd Blanche named acting U.S. attorney general after Pam Bondi fired. What this means for Canadian investors: antitrust enforcement shifts, M&A regulatory risk, and cross-border deal timelines.